Altered peptide ligands (APL) have the potential to modulate pathogenic T cell reactivity. High concentrations of APL, however, are required to achieve efficient blocking of the T cell response. We have therefore investigated whether improved delivery of APL to professional antigen-presenting cells (APC) can lead to more efficient application of such peptides. For this purpose APL were bis-mannosylated in order to facilitate their uptake by mannose receptorpositive dendritic cells (DC) in vitro. We present evidence that a 100-to 1000-fold lower concentration of bis-mannosylated APL was sufficient for complete blocking of the proliferative T cell response against the agonist peptide compared to the non-mannosylated APL. Moreover, bis-mannosylated APL were similarly effective in the inhibition of the T cell response against whole protein antigens. In contrast, unrelated, bis-mannosylated class II binding peptides were ineffective, indicating that the increased efficiency of the mannosylated APL was not due to competition for binding to class II molecules. Furthermore, a strong increase in the efficiency of presentation of APL was also observed when macrophages and peripheral blood mononuclear cells were used as APC. Thus, bis-mannosylation of APL greatly increases their potency to inhibit proliferative T cell responses. Moreover, it is likely that the use of bismannosylated APL will result in preferential presentation by mannose receptor-positive, professional APC. These results may be of relevance for more effective use of APL for immunoregulation in vivo.
Introduction
T cell stimulatory peptides can be converted into peptides with partial agonistic or antagonistic properties by amino acid substitutions in T cell receptor (TCR) contact residues. Such altered peptide ligands (APL) can (partially) block the T cell response to the agonist (1-3). The application of APL can lead to a wide range of biological effects such as the induction of an altered cytokine profile (4), clonal anergy (5) and inhibition of the T cell response to the agonist (6, 7) . These immunomodulatory properties of APL have received wide attention since they can be used to interfere in unwanted T cell reactivity during, for example, autoimmune diseases (8) (9) (10) , allergy and transplant rejection. High concentrations of APL peptides, however, are usually required to accomplish interference in T cell responses, hampering the in vivo application (4) (5) (6) (11) (12) (13) (14) .
The first two authors contributed equally to this work Correspondence to: F. Koning Transmitting editor: A. McMichael Received 9 March 1998, accepted 14 May 1998 The efficiency of antigen uptake by APC is a critical parameter in the process of MHC class II-restricted antigen presentation. Antigens can be taken up via either receptormediated endocytosis (15) or fluid-phase endocytosis (16) . The internalization mediated by the mannose receptor has been found to be one of the major mechanisms for efficient antigen uptake in dendritic cells (DC) (17) . Mannose receptors are expressed primarily by DC, macrophages and epithelial cells (18, 19) . Recently, we and others have observed that targeting of antigens to the mannose receptor pathway resulted in highly efficient presentation to antigenspecific T cells (20, 21) . Moreover, we demonstrated that not only mannosylated proteins but also bis-mannosylated peptides were presented in a superior fashion compared to their non-mannosylated analogs (20) . We therefore decided to investigate whether bis-mannosylation of APL enhanced their immunomodulatory efficacy in a similar fashion.
Methods

Peptides
Peptides were synthesized by solid-phase strategies on an automated multiple peptide synthesizer (Abimed AMS 422) (22) . The following peptides were synthesized: mycobacterial HSP65 (amino acids 3-14), KTIAYDEEARRG; HSP65 (amino acids 3-14, A → Q), KTIQYDEEARRGL; HSP65 (amino acids 3-14, Y → S), KTIASDEEARRGL (23); (amino acids 3-14, polyAla), KAIAADAAAAAA; invariant chain-derived clip peptide, KAMRMATPLLMQA, imogen (amino acids 54-70) KSPSLWEI-EFAKQLASV; imogen (amino acids 54-70, E → D), KSPSLWD-IEFAKQLASV; imogen (amino acids 54-70, K → R), KSPSLWEIEFARQLASV; imogen (amino acids 54-70, F → I), KSPSLWEIEIAKQLASV. In case of the imogen peptides, that contain a K at position 12, this residue was introduced during synthesis as the DDE-protected derivative. The DDE protection was removed after mannosylation, essentially as described (24) . For mannosylation of peptides and proteins 4 mg of α-D-mannopyranosylphenylisothiocyanate (Sigma, St Louis, MO) and 2 µl of NMM was added to a solution of 2 mg of synthetic peptide or protein in 200 µl DMSO. The reaction mixture was stirred overnight, after which the excess α-D-mannopyranosylphenylisothiocyanate was hydrolysed by the addition of 100 µl Tris-HCl (pH 9.5, 1 M) for 1 h. The mannosylated peptides were HPLC-purified by gradient elution (water-acetonitrile, 0.1% TFA) on reversed phase. The integrity of the purified glyco-peptides was determined by laser desorption time-of-flight mass spectrometry on a Lasermat mass spectrometer (Finnigan MAT, Hemel Hempstead, UK). Calibration was performed with peptides of known molecular mass, either as external or as internal references. The purified glyco-peptides were subsequently lyophilized in aliquots and stored at -20°C until use.
Isolation of human DC from peripheral blood DC were prepared according to the protocol of Sallusto and Lanzavecchia (25) . Briefly, peripheral blood mononuclear cells (PBMC) were isolated from heparinized fresh buffy coats by flotation on Ficoll (Pharmacia, Uppsala, Sweden). After a T cell depletion using triethanolamine-treated sheep red blood cells (Biotrading Benelux, Mijdrecht, The Netherlands), the cells were resuspended in Iscove's plus glutamax (Gibco, Grand Island, NY) or Hanks (Gibco) and allowed to adhere to six-well plates (Costar, Cambridge, MA). After 2 h at 37°C in a humidified CO 2 incubator the non-adherent cells were removed by several wash steps with Hanks (Gibco). The adherent cells were cultured in Iscove's/10% FCS supplemented with 800 U/ml granulocyte macrophage colony stimulating factor (GM-CSF) (kindly provided by Dr S. Osanto, Department of Clinical Oncology, Leiden University Medical Centre ) and 1000 U/ml IL-4 (Amgen, Thousand Oaks, CA). At day 4, culture medium containing 800 U/ml GM-CSF and 1000 U/ml IL-4 was added to the cultured DC. DC were used for experiments at day 6.
T cell proliferation assays
The T cell clone RP15.1.1 is DR17 restricted and specific for the mycobacterial HSP65-derived 3-14 peptide (23, 28) . The T cell clone 1C6 is DR1 restricted and specific for a peptide corresponding to the 38 kDa islet mitochondrial antigen (imogen 55-70) (26, 27) . Proliferation was assayed by culturing 1ϫ10 4 T cells in 96-well flat-bottom microplates with 5ϫ10 3 HLA-matched DC or 5ϫ10 4 irradiated (3000 rad) HLA-matched PBMC in the absence or presence of various concentrations of peptides, purified protein derivative (PPD; Statens Seruminstitute, Copenhagen, Denmark) or mycobacterial HSP65. Inhibition by APL was studied in co-incubation and preincubation T cell proliferation assays. In co-incubation assays, T cells were co-cultured with DC or PBMC in the absence or presence of agonist peptides and bis-mannosylated or non-mannosylated APL. In preincubation assays, irradiated HLA-matched DC or PBMC were incubated with the agonist peptide and T cells for 6 h, after which the bismannosylated or non-mannosylated APL peptides were added.
Affinity purification of DR molecules and DR-peptide binding assay
As a source of DR17 molecules the EBV-BLCL HAR (DRB1*0301), homozygous for HLA-DR17, was used. Cells were cultured in RPMI 1640, 2 mM L-glutamine, 100 U/100 mg/ml penicillin/streptomycin and 10% heat-inactivated FCS (Gibco). Cells were lysed at a concentration of 10 8 cells/ml in 50 mM Tris-HCl, pH 8.5, containing 2% Renex (Accurate Chemicals and Scientific, Westbury, NY), 150 mM NaCl, 5 mM EDTA and 2 mM PMSF. Lysates were cleared of nuclear and other debris by centrifugation at 10,000 g for 20 min. DR molecules were affinity-purified as described previously (28) . Purified DR molecules (60-600 nM) were incubated at pH 4.5 for 48 h with 100 fmol fluorescent labeled peptide in 15 ml 100 mM Na phosphate buffer containing 75 mM NaCl, 1 mM CHAPS (Merck, Darmstadt, Germany) and 15% (v/v) CH 3 CN in the presence of a protease inhibitor mixture. The final concentrations of protease inhibitors were: 1 mM chymostatin, 5 mM leupeptin, 10 mM pepstatin A, 1 mM EDTA and 200 mM pefabloc. The standard fluorescence-labeled peptide, hsp65 p3-13, was labeled as described previously (1) . In preliminary experiments, each DR preparation was titered in the presence of 100 fmol standard peptide to determine the DR concentration necessary to bind 10-20% of the total fluorescent signal. All subsequent inhibition assays were then performed at this concentration. Peptides, of which the DR binding capacity was to be determined, were added to DR molecules simultaneously with the standard peptide. The DRpeptide complexes were separated from free peptide by gel filtration on a Synchropak GPC 100 column (250ϫ4.6 mm; Synchrom, Lafayette, IN). Fluorescent emission was measured at 528 nm on a Jasco FP-920 fluorescence detector (B & L Systems, Zoetermeer, The Netherlands). The percentage of labeled peptide bound was calculated as the amount of fluorescence bound to MHC divided by total fluorescence. The concentration of peptide inhibitor yielding 50% inhibition (IC 50 ) was deduced from the dose-response curve.
Results and discussion
To evaluate the effect of bis-mannosylation on the activity of agonist peptides and APL we used the HLA-DR17-restricted, HSP65-specific T cell clone RP15.1. This T cell clone is specific for a peptide corresponding to amino acids 3-14 of HSP65 and APL with antagonistic properties described previously (23) . In agreement with our previous results (20) , 1000-fold less of the bis-mannosylated form of the 3-14 agonist peptide was required for the induction of full T cell activation compared to the non-mannosylated analog (Fig.  1A) . Next, the T cells were co-cultured with HLA-DR-matched DC in the absence or presence of the non-mannosylated agonist peptide and a concentration range of bis-mannosylated or non-mannosylated APL. A normal proliferative response of the T cell clone was observed in response to both the optimal dose (1 nmol/ml, Fig. 1A ) and suboptimal dose (0.025 nmol/ml, Fig. 1B ) of the agonist peptide. Complete blocking of these responses were only observed when a large excess of the APL (amino acids 3-14, Y → S) was added to the assay, typically 1000-fold ( Fig. 1A and B) . Strikingly, 1000-fold lower concentration of the bis-mannosylated form of this APL was sufficient for a similar inhibition of the proliferative T cell response against the agonist (Fig. 1A and B) . Thus, bis-mannosylation increases the presentation of agonist and antagonist peptides to a similar extent. Consequently, when agonist and antagonist were both used in their bis-mannosylated form, 1000-fold excess of the antagonist was again required to obtain blocking of the T cell response (not shown).
Next, we determined the effect of mannosylation on the activity of a second APL (amino acids 3-14, A → Q). In the non-mannosylated form no significant inhibition of the response to the agonist peptide was achieved at the concentrations used (Fig. 1C) . Bis-mannosylation, however, significantly enhanced the capacity of this APL to block the T cell response to the agonist peptide (Fig. 1C) .
Importantly, the T cell response against the agonist peptide could not be inhibited by a bis-mannosylated DR17 binding peptide that bears no structure homology with the agonist or by a bis-mannosylated poly-Ala peptide containing the DR17 peptide binding anchor residues (Fig. 1D) . In order to rule out any possible effects of the bis-mannosylation on the binding of the peptides to DR17, the non-mannosylated and bis-mannosylated forms of the agonist peptide and related APL were tested in a DR17-specific, cell-free peptide binding assay. No significant differences in the IC 50 values between the mannosylated and non-mannosylated forms of the peptides were observed (Table 1) . Thus, for these peptides mannosylation does not influence their capacity to bind to DR17. In addition, we tested if the bis-mannosylated APL (amino acids 3-14, Y → S) could also effectively block the T cell response when the DC had been pulsed with the agonist peptide for 6 h prior to the addition of the T cells and the APL. The results obtained demonstrate that the bismannosylated APL were 100-to 1000-fold more effective compared to their non-mannosylated analogs (results not shown). Finally, we have previously shown that the enhanced presentation of bis-mannosylated can be blocked by mannan (20) . Together, these results strongly indicate that the enhanced capacity of bis-mannosylated APL to inhibit T cell responses is not due to competition for binding to HLA-DR.
Moreover, it has been demonstrated that mannose receptormediated uptake results in delivery of the mannose receptor ligand to the endosomal compartment where class II molecules are loaded with peptide (20, 21) . The enhanced efficiency of mannosylated APL is thus likely the results of mannose receptor-mediated uptake which leads to more efficient loading onto intracellular class II molecules destined for cell surface expression. Subsequently, we examined whether bis-mannosylated APL were equally effective in the inhibition of T cell proliferation induced by naturally processed protein antigens. To this end, T cells were co-cultured with DC, an optimal concentration of either HSP65 or PPD, and a concentration range of the (bismannosylated) APL. We again observed that for inhibition of the T cell responses 100-to 1000-fold less of the bismannosylated APL was required compared to the non-mannosylated counterpart (Fig. 2A) .
In order to determine whether the effect of mannosylation on the enhanced efficiency of APL is a general phenomenon, we investigated the effects of mannosylation in a second agonist-APL test system. For this purpose we used a T cell clone specific for a peptide corresponding to the 38 kDa islet mitochondrial antigen (imogen 55-70) (26, 27) for which APL have been described (Geluk et al., submitted). We observed 
The HSP65 (amino acids 3-13) peptide was presented by either DC, macrophages or PBMC in the presence of a concentration range of either the non-mannosylated or the bis-mannosylated APL HSP65 (amino acids 3-14) Y → S. IC 50 values (µM) were calculated from the resulting dose-response curves.
that for blocking of the T cell response to the agonist, 100-fold less of the bis-mannosylated APL was required compared to the non-mannosylated analog (Fig. 2B ).
Finally, we tested whether the enhanced activity of APL could also be observed with other sources of APC. We observed that, compared to the non-mannosylated HSP65 (amino acids 3-14, Y → S) APL, 100-fold less of the bis-mannosylated APL was sufficient to obtain half-maximal inhibition of the T cell response against the agonist when PBMC or GM-CSF cultured human macrophages were used as APC (Table 2) . Thus, mannose receptor-positive macrophages and monocytes in PBMC, that become mannose receptor-positive during culture (results not shown), are also effective in the presentation of mannosylated APL.
Several problems restrict the use of APL in vivo First of all, the activity of APL is usually limited to only few peptidespecific T cells clones and is thus not capable of blocking polyclonal antigen-specific T cell responses. Secondly, the need for high amounts of APL to induce significant blocking of the response to the agonist. The present study does not address the first issue. The results, however, clearly indicate that for the model antigens used in this study, mannosylation of APL strongly enhances their potency to block the response to an agonist peptide in vitro, reducing the need for a large excess of APL. It should be noted that this approach is not likely to work for MHC class I-restricted peptides: due to the mannose receptor-mediated uptake the peptides are delivered primarily to the endosomal compartment and not to the cytosol. Consequently, we have so far been unable to demonstrate enhanced presentation of mannosylated MHC class I-restricted peptides (unpublished observations). Clearly, more work will be required to evaluate the feasability of this approach for in vivo applications. First of all, mannosylated peptides may induce unwanted T cell responses to the modified mannosylated peptide which could result in cell death and/or tissue destruction. Also, soluble mannose binding proteins in the blood stream are likely to clear a proportion of i.v. injected bis-mannosylated peptides before they can be bound by mannose receptors on APC, reducing the efficiency. This may be avoided by the administration of a high-affinity ligand for soluble mannose binding proteins prior to the mannosylated APL. Alternatively, intradermal application may be effective since mannose receptor-positive cells are abundant in the dermis. It is also not known if the application of mannosylated APL will lead to long-lasting immunosuppression. These issues will have to be investigated in future studies.
In conclusion, bis-mannosylation of APL facilitates their uptake by mannose receptor-positive APC which results in a strongly enhanced capacity to block the proliferative T cell response to agonists. Such bis-mannosylated APL are effective at nanomolar concentrations. This may facilitate the in vivo application of APL.
